Nebenwirkungen · Casgevy
Casgevy 4 - 13 × 106 cells/mL dispersion for infusion · Abschnitt 4.8 · PDF-Seite 13
HOS-149359 · Präparat HOS-100036
The safety of Casgevy was evaluated in 31 adolescent patients aged 12 to less than 18 years with TDT or SCD. The median (min, max) age of adolescent TDT patients was 14 (12, 17) years, and for SCD patients was 15 (12, 17) years. The median (min, max) duration of follow-up was 19.6 (2.1, 26.6) months for adolescent TDT patients and 14.7 (2.5, 18.7) months for adolescent SCD patients. The safety profile was generally consistent among adolescent and adult patients. Engraftment times were similar in adolescent and adult patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-12T14:50:00Z · SHA-256 88371a72474d6cc8476d82edcf74bc7f8b779e890b5a4d457f22edba3fd2067e · Passage 83a98a68e6b04e92257268e7ed3af060f5b43448283f58bacbf45854b95e11f7 · Zeichen 16180–16711 im Abschnitt